As multiple companies have – with varying degrees of success – sought to develop next-generation drugs for treating overweight and obesity, Metsera has shown that it is feasible to administer its GLP-1 receptor agonist candidate MET-097i monthly rather than weekly. The VC-backed start-up is now planning to expand clinical development of the drug at a time when the market remains open for successors to the two marketed drugs in the class.
Metsera Confirms Feasibility Of Monthly Dosing Of Obesity Drug Candidate
The Phase IIa data for the next-generation GLP-1 agonist showed a decent efficacy profile with weekly dosing, but the company said it also supports giving the drug monthly.
